Syndax Pharmaceuticals (SNDX) EBITDA Margin (2015 - 2026)
Syndax Pharmaceuticals' (SNDX) quarterly EBITDA Margin came in at 52.73% in Q1 2026, up 36518.0% year-on-year from N/an in Q1 2025, and up 42.06% quarter-over-quarter from 91.01% in Q4 2025.
Syndax Pharmaceuticals (SNDX) EBITDA Margin (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' EBITDA Margin history runs 10 years deep, the most recent figure standing at 52.73% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 36518.0% year-over-year to 52.73% in Q1 2026; TTM through Mar 2026 was 102.81%, a 68379.0% increase from a year earlier, with the FY2025 full-year figure at 158.45%, up 127598.0% from the prior year.
- EBITDA Margin improved to 52.73% in Q1 2026 per SNDX's latest filing, from 91.01% in the prior quarter.
- Across five years, EBITDA Margin topped out at 52.73% in Q1 2026 and bottomed at 2120.46% in Q2 2024.
- The 3-year median for EBITDA Margin is 300.31% (2025), against an average of 620.17%.
- Across the five-year window, EBITDA Margin surged 193775 bps in 2025 and soared 36518 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 1254.75% in 2024, then jumped by 93 bps to 91.01% in 2025, then soared by 42 bps to 52.73% in 2026.
- Per Business Quant, the three latest SNDX EBITDA Margin figures stand at 52.73% (Q1 2026), 91.01% (Q4 2025), and 125.19% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Syndax Pharmaceuticals | 1.87 Bn | 1.52 Bn | 53.02 Mn | -52.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.73% |
| Dec 31, 2025 | -91.01% |
| Sep 30, 2025 | -125.19% |
| Jun 30, 2025 | -182.71% |
| Mar 31, 2025 | -417.91% |
| Dec 31, 2024 | -1,254.75% |
| Sep 30, 2024 | -716.62% |
| Jun 30, 2024 | -2,120.46% |
| Dec 31, 2021 | 75.65% |
| Sep 30, 2021 | -161.87% |
| Jun 30, 2021 | -5,892.88% |
| Mar 31, 2021 | -7,167.02% |
| Dec 31, 2020 | -5,226.32% |
| Sep 30, 2020 | -5,238.26% |
| Jun 30, 2020 | -4,382.59% |
| Mar 31, 2020 | -3,984.17% |
| Dec 31, 2019 | -3,738.16% |
| Sep 30, 2019 | -3,469.39% |
| Jun 30, 2019 | -4,056.46% |
| Mar 31, 2019 | -3,907.92% |